Mergers & Acquisitions ·
Acrivon acquires oral JAK1 inhibitor ACR-525 and PKCθ program from Aqilion for undisclosed cash
ACRVAcrivon Therapeutics, Inc.
Acrivon Therapeutics has acquired the rights to ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a preclinical PKCθ inhibitor program from Aqilion AB. The transaction includes associated intellectual property, data, regulatory filings, and drug supply for undisclosed cash consideration with no future milestone or royalty obligations. Concurrently, the company terminated all future royalty and milestone obligations on ACR-525 previously agreed to between Aqilion and LEO Pharma. The acquisition establishes immunology and inflammation as a strategic pillar alongside oncology. Acrivon Therapeutics is a clinical-stage biotechnology company developing precision medicines using its proprietary AP3 platform.